GlassScriptPhysician profile
Misti L Ready
NPI 1750696498
$5,423.98
in general payments reported to CMS, 2019-2025
23 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $896 · 2022: $806 · 2023: $2,536 · 2024: $721 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Travel and Lodging: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.67 |
| Travel and Lodging | $897.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,693.80 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Axonics, INC. | $1,079.50 | 2023 | Axonics |
| Enterra Medical, INC. | $620.88 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $408.85 | 2023-2025 | Voquezna |
| Abbvie INC. | $351.21 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.81 | 2021-2025 | Entyvio |
| Qol Medical, LLC | $136.47 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $130.39 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $127.01 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $89.66 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $87.99 | 2021-2024 | Linzess |
| Aimmune Therapeutics, INC. | $73.77 | 2024-2025 | Vowst |
| Ardelyx, INC. | $73.27 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $61.02 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $58.48 | 2022-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $49.70 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $44.69 | 2023 | Aemcolo, Talicia, Movantik |
| Pharmacosmos Therapeutics INC. | $31.19 | 2021 | |
| Ferring Pharmaceuticals INC. | $25.94 | 2022-2023 | Rebyota |
| Genzyme Corporation | $21.54 | 2025 | |
| Madrigal Pharmaceuticals | $21.07 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $17.13 | 2022 | |
| Novo Nordisk INC | $16.61 | 2025 | Saxenda, Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misti Ready listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.